Saturday, July 20, 2024
HomeFunding Miravast Asset Management LLC Secures Miravast ILS Credit Opportunities II LP...

[Funding news] Miravast Asset Management LLC Secures Miravast ILS Credit Opportunities II LP (“Fund II”) at $346 Million

Miravast Asset Management LLC, a leading vertically integrated investment manager with deep experience underwriting longevity risk and investing in life settlements is pleased to share that it recently completed fundraising for Miravast ILS Credit Opportunities II LP ("Fund II") with $346 million of fund commitments.

Miravast Asset Management LLC, a leading vertically integrated investment manager with deep experience underwriting longevity risk and investing in life settlements is pleased to share that it recently completed fundraising for Miravast ILS Credit Opportunities II LP (“Fund II”) with $346 million of fund commitments.

Dave Beckelman, Chief Executive Officer said, “Closing Fund II represents an important milestone for Miravast. We continue to believe Miravast offers institutional investors an unparalleled team of medical underwriting and actuarial experts. The LP support we are fortunate to have for Fund II further exemplifies the confidence that the institutional LP community has in the Miravast team,”.

Dave Cherkas, Executive Vice President said, “As with its predecessor, Fund II has a global institutional investor base. We are grateful to have support from existing and new institutional LP’s as we execute our strategy. We have invested a portion of Fund II’s committed capital and will continue to leverage our in-house expertise as we pursue additional investments,”.

About Miravast Asset Management LLC

Founded in 2012, Miravast is a vertically integrated asset management firm with approximately $1.2 billion of assets under management. Miravast’s experience in life insurance product design and medical underwriting, coupled with our perspective on investment structures, allows us to help institutional investors navigate the complexities of investing in longevity risk, chiefly life settlements.

Read also – MedPharm and Tergus Pharma Merger Forms Topical and Transepithelial CDMO Leader

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular